Equity Overview
Price & Market Data
Price: $1.23
Daily Change: +$0.02 / 1.63%
Daily Range: $1.15 - $1.25
Market Cap: $13,917,204
Daily Volume: 176,946
Performance Metrics
1 Week: -12.14%
1 Month: -32.04%
3 Months: 10.81%
6 Months: -39.11%
1 Year: -68.46%
YTD: -60.45%
Company Details
Employees: 5
Sector: Health technology
Industry: Biotechnology
Country:
Details
Marker Therapeutics, Inc., a clinical-stage immuno-oncology company, engages in the development and commercialization of novel T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications. Its multi tumor associated antigen-specific T cell technology is based on the manufacture of non-engineered tumor-specific T cells that recognize multiple tumor-associated antigens. The company also develops MT-401-OTS for the treatment of acute myeloid leukemia AND myelodysplastic syndromes; and MT-601 to treat lymphoma and pancreatic cancer. Marker Therapeutics, Inc. is headquartered in Houston, Texas.